CIMB, Pharmaniaga team up to boost financial flexibility for healthcare SMEs
The partnership aims to provide greater financial flexibility to clinics, pharmacies and medical buyers across the sector, CIMB said.
"Under the collaboration, CIMB and Pharmaniaga will offer enhanced payment flexibility to downstream buyers including private clinics and independent pharmacies through CIMB SME BusinessCard," the bank said in a statement today.
Businesses can enjoy up to 50 days of extended credit when purchasing medical supplies using the card and get unlimited 0.5 per cent cash rebate on all Pharmaniaga purchases, offering a valuable incentive to improve cash flow and optimise working capital.
Lawrence Loh, CIMB Group co-chief executive officer (group commercial and transaction banking), said that by offering extended credit terms and early settlement incentives, the bank is helping clinics, pharmacies, and medical buyers better manage cash flow and reduce operational strain while enhancing the quality of care they provide.
"We aim to further expand our healthcare SME portfolio, driven by strategic collaborations with ecosystem partners and enhanced access to digital, sector-focused financing solutions," he said in the statement.
Meanwhile, Pharmaniaga managing director Zulkifli Jafar said this collaboration reflects the pharmaceutical company's strong commitment to supporting its valued business partners with practical financial solutions to manage their supply chains more effectively.
"By offering greater payment flexibility and tailored financing options, we aim to empower our partners to grow sustainably while ensuring continuous access to a broad range of pharmaceutical products to serve their clients with confidence," he said.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New Straits Times
5 hours ago
- New Straits Times
Tariff uncertainties to pose little impact on CIMB's FY2026: Group CEO
KUALA LUMPUR: CIMB Group Holdings Bhd says the prevailing uncertainty surrounding global tariff policies will not have a direct impact on its financial performance for the financial year ending 2026 (FY2026). This will be due to the group's diversified income strategy and sustainable operational efficiency. CIMB Group chief executive officer Novan Amirudin said while global tariffs could potentially weigh on regional economic growth, the impact on the bank remains limited and largely depends on how the additional costs are distributed along the supply chain. "It depends on whether the costs are borne by producers in Asean, consumers in the United States, or absorbed by governments through incentives and supportive policies," he said during a fireside chat held in conjunction with CIMB's Asean Media Day today. He added that if restrictions on exports from China to the United States prompt manufacturers to relocate to Asean, any resulting oversupply could put pressure on local producers. "This situation could slow regional growth and indirectly affect the financial sector, as loan growth is closely tied to economic activity," he explained. Nevertheless, he said CIMB does not rely solely on interest income but has also strengthened its non-interest income streams. "About 30 per cent of the group's income comes from non-interest sources, including transaction fees, foreign exchange, payment solutions and advisory services. "These initiatives are aligned with our Forward 30 strategy, which emphasises revenue stream diversification," he said. On the recent Overnight Policy Rate (OPR) cut by Bank Negara Malaysia, he said the move impacts the lending rates offered to customers. CIMB also adjusted its deposit rates, such as fixed deposits, which are now at lower levels. "A lower OPR typically reduces funding costs. Therefore, the net impact on the bank depends on how much lending and deposit rates are adjusted. "If we are able to reduce deposit rates further, we can still maintain our net interest margins," he said.
BusinessToday
5 hours ago
- BusinessToday
CIMB Expected To Deliver "Decent" Performance In Q2
CIMB Group is expected to deliver a 'decent' performance for its second quarter of 2025, supported by stable net interest margins (NIMs) and strong non-interest income, according to a pre-results analysis by Maybank Research. The research firm has maintained a 'Hold' call on CIMB with an unchanged target price of MYR7.60, pending the official release of the group's results. CIMB Group is scheduled to announce its 2Q25 results on August 29, following the release of its Indonesian subsidiary, CIMB Niaga, on July 30. Maybank Research highlights several positive factors contributing to the bank's expected performance for the quarter ended June 30: Net interest margins (NIMs) are likely to have remained stable quarter-on-quarter, with positive traction in Malaysia and Singapore offsetting some compression in its Thai and Indonesian operations. The report anticipates a sequential increase in non-interest income, driven by sustained trading and foreign exchange activities. Asset quality is expected to remain stable, with credit costs likely to be benign. The report notes that CIMB's credit cost guidance of 25-35 basis points for the full year 2025 remains intact, suggesting a potential positive surprise as Maybank's own forecast for the year is a slightly higher 36 basis points. However, the report points to one area where results may be weaker than expected: loan growth. According to Maybank Research, the group has been cautious in lending to the corporate and commercial sectors due to competitive yields. This has led the research house to forecast a loan growth of 4.5% for the full year, below CIMB Group's own target of 5-7%. Despite the mixed outlook, Maybank Research is keeping its earnings forecasts unchanged, believing the positive elements of stable margins and strong non-interest income will support its existing assumptions for the group. The report concludes that while the group is positioned for stability in the near term, its 'Hold' rating reflects a cautious but fair valuation at this juncture. Related
The Star
3 days ago
- The Star
Tech index bucks market trend, national semiconductor strategy attracts RM63bil in investments
KUALA LUMPUR: The Bursa Malaysia Technology Index inched up 0.04 of a point to 52.36 while most of the other sectoral indices remained in negative territory. This may be due to Prime Minister Datuk Seri Anwar Ibrahim's announcement yesterday that the National Semiconductor Strategy (NSS), launched in May 2024, has attracted RM63 billion in investments, comprising RM58 billion in foreign direct investments and RM5.2 billion in domestic direct investments. "Malaysia's transition from a back-end assembly base to a design-to-packaging semiconductor hub remains a work in progress. "However, we are encouraged to see that the NSS is gaining investor traction, institutional support, and regional momentum. With RM63 billion in committed investments, an increase in local champions, and stronger ASEAN alignment, Malaysia is positioning itself as a neutral, indispensable node in the global chip supply chain,' it added. CIMB affirmed that this is one of the key advantages in ensuring Malaysia remains an attractive destination for semiconductor manufacturing globally. At lunch break, Vitrox shares went up 20 sen to RM3.99, Infomina was 11 sen better at RM1.07 and SMRT was 6.5 sen higher at 90.5 sen. - Bernama Trading ideas: MMAG, Keyfield, KAB, Rimbunan Sawit, Jentayu, AYS, Country Heights, Metronic, Nestle, ViTrox, Oriental Interest, KIP REIT, Luxchem, Betamek
